IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc.

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent

Question(s) Presented

“Whether, pursuant to the United States’ obligations under the TRIPS Agreement, codified at 19 U.S.C. § 3511, a court construing the claims of a U.S. patent may give no weight to a foreign priority patent application, despite its submission to the U.S. Patent & Trademark Office during prosecution of the patent-in-question, because it is written in a foreign language and exhibits minor differences from the U.S. patent resulting from a translator’s judgment.”

Posts About this Case

Date
Proceedings and Orders
March 16, 2021
DISTRIBUTED for Conference of 4/1/2021.
April 5, 2021
Petition DENIED.